No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Sotac Pharmaceuticals Ltd. is an India-based company operating within the pharmaceutical industry, specializing in the manufacturing of a diverse range of pharmaceutical formulations. The company functions primarily as a Contract Development and Manufacturing Organization (CDMO) and third-party manufacturer, serving both domestic and international clients. Its product portfolio includes various finished formulations such as tablets (general, beta-lactam, coated, and uncoated), capsules (general and beta-lactam), oral liquids, dry syrups, and external preparations like nasal sprays, relief sprays, and creams. Sotac Pharmaceuticals produces pharmaceuticals across numerous therapeutic areas, including anti-diabetic, anti-psychotic, vitamin and mineral supplements, anti-cold, anti-allergic, dermatological, antacid, anti-ulcerant, anti-emetic, cardiac, anti-hypertensive, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (both IP-Lactams and Non-IP-Lactams), anti-fungal, and cephalosporin products. Beyond manufacturing, the company provides essential services to the pharmaceutical sector, including regulatory services, containment solutions, formulation development, clinical batch production, commercial scale production, and packaging. Sotac Pharmaceuticals exports to over 20 countries globally, with the United States being a significant international market, and maintains a strong presence across 14 major states in India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sotac Pharmaceuticals Ltd. (SOTAC.NS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Sotac Pharmaceuticals Ltd. is an India-based company operating within the pharmaceutical industry, specializing in the manufacturing of a diverse range of pharmaceutical formulations. The company functions primarily as a Contract Development and Manufacturing Organization (CDMO) and third-party manufacturer, serving both domestic and international clients. Its product portfolio includes various finished formulations such as tablets (general, beta-lactam, coated, and uncoated), capsules (general and beta-lactam), oral liquids, dry syrups, and external preparations like nasal sprays, relief sprays, and creams. Sotac Pharmaceuticals produces pharmaceuticals across numerous therapeutic areas, including anti-diabetic, anti-psychotic, vitamin and mineral supplements, anti-cold, anti-allergic, dermatological, antacid, anti-ulcerant, anti-emetic, cardiac, anti-hypertensive, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (both IP-Lactams and Non-IP-Lactams), anti-fungal, and cephalosporin products. Beyond manufacturing, the company provides essential services to the pharmaceutical sector, including regulatory services, containment solutions, formulation development, clinical batch production, commercial scale production, and packaging. Sotac Pharmaceuticals exports to over 20 countries globally, with the United States being a significant international market, and maintains a strong presence across 14 major states in India.